Ann: Appendix 4C - June 2018 quarter, page-11

1 hour ago | Daniel Paproth


* did an article on respiratory stocks that featured IVX....

https://unauthorised investment adv...piratory-stocks-to-get-you-feeling-breathless


There are more than a dozen ASX stocks focused on the respiratory space — from trying to tackle asthma
A * review of 13 small cap respiratory stocks has found that the majority are up year-on-year — led by one company that had a stellar 2018 financial year.
Invion (ASX:IVX), which is testing a drug called INV104, is up a huge 1358 per cent over the past 12 months, going from 0.2c to 3.5c earlier today:
https://unauthorised investment advice/wp-content/uploads/2018/08/Share-Price-41.jpg
Invion shares (ASX:IVX) over the past year
The drug works by blocking the actions of leukotrienes, preventing the increased mucus production, inflammation and narrowing of the airways that occurs in asthma.